Radioimmunotherapy for Treatment of Acute Leukemia

Abstract : Acute leukemias are characterized by accumulation of immature cells (blasts) and reduced production of healthy hematopoietic elements. According to the lineage origin, two major leukemias can be distinguished: acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Although the survival rate for pediatric ALL is close to 90%, half of the young adults with AML or ALL and approximately 90% of older patients with AML or ALL still die of their disease, raising the need for innovative therapeutic approaches. As almost all leukemic blasts express specific surface antigens, targeted immunotherapy appears to be particularly promising. However, published results of immunotherapy alone are generally modest. Radioimmuno-therapy (RIT) brings additional therapeutic mechanisms using radiolabeled monoclonal antibodies (mAbs) directed to tumor antigens, thus adding radiobiological cytotoxicity to immunologic cytotoxicity. Because of the high radiosensitivity of tumor cells and the diffuse widespread nature of the disease, making it rapidly accessible to circulating radiolabeled mAbs, acute leukemias represent relevant indications for RIT. With the development of recombinant and humanized mAbs, innovative radionuclides, and more efficient radiolabeling and pretargeting techniques, RIT has significantly improved over the last 10 years. Different approaches of α and β RIT targeting CD22, CD33, CD45, or CD66 antigens have already been evaluated or are currently being developed in the treatment of acute leukemia. This review summarizes the preclinical and clinical studies demonstrating the potential of RIT in treatment of AML and ALL. Semin Nucl Med 46:135-146 C
Type de document :
Article dans une revue
Seminars in Nuclear Medicine, Elsevier, 2016, 46, pp.135-146. 〈10.1053/j.semnuclmed.2015.10.007〉
Liste complète des métadonnées

Littérature citée [67 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01280232
Contributeur : Elizabeth Bernardo <>
Soumis le : lundi 29 février 2016 - 10:59:49
Dernière modification le : jeudi 15 mars 2018 - 14:10:54
Document(s) archivé(s) le : dimanche 13 novembre 2016 - 05:10:14

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Caroline Bodet-Milin, Françoise Kraeber-Bodéré, Thomas Eugène, François Guérard, Joëlle Gaschet, et al.. Radioimmunotherapy for Treatment of Acute Leukemia. Seminars in Nuclear Medicine, Elsevier, 2016, 46, pp.135-146. 〈10.1053/j.semnuclmed.2015.10.007〉. 〈inserm-01280232〉

Partager

Métriques

Consultations de la notice

70